String Of Positives For Lupin Lifts Outlook

Regulatory clearances for some key sites awaited

Tentative FDA approval for Lupin’s arformoterol tartrate inhalation solution and a potential EC nod for etanercept are seen aiding the company’s prospects in FY2021. Besides, success in a Phase III trial for secnidazole to treat trichomoniasis bodes well, though manufacturing clearances and continuity will also be closely watched.

Storm_To_Sun_Paper
Will Lupin See A Turnaround in FY21? • Source: Shutterstock

Going by recent events, Lupin Ltd. can count on new product launches in major markets like the US and EU to aid its FY2021 performance even while the outlook on production remains mixed with benefits of regulatory approvals for some plants shaved to some extent by overall operational difficulties due to the COVID-19 related ongoing lockdown in India.

The company secured tentative approval from the US Food and Drug Administration (FDA) for a generic version of Sunovion...

More from Manufacturing

More from Business

  • How A New Healthcare Dialogue Is Driving Market Access In Mexico

    Companies stand a better chance of securing public reimbursement in Mexico for innovative medicines if they understand changing approaches to healthcare. The shift means the emergence of managed entry agreements and a focus on economic impact, explains AMIIF, Mexico's research-based pharmaceutical industry association.

  • How Novartis Is Elevating CVD Outcomes, Driving ‘Personalized Access’ In APMA

    Novartis’s APMA chief outlines the company’s tailored approach to deliver long-term outcomes, novel access solutions via innovative financing options and shape the CVD disease ecosystem in the extraordinarily diverse region. Partnering to build AI infrastructure is another key prong.

  • India Rare Diseases: Court Shows Path For Policy Action, Funding, Price Issues-- Test-2

    A court order encompassing funding, drug pricing, clinical trials and overall policy implementation aspects is expected to bring about a paradigm shift in the treatment of rare diseases in India. Sarepta, Roche and Sanofi are among the key players that have been part of pricing discussions.